智通财经APP获悉，周一，Mineralys Therapeutics(MLYS.US)逆势暴涨超53%，报16.25美元。消息面上，该公司周一报告了其Lorundrostat药物候选治疗不受控制或耐药性高血压的两项关键研究的积极初步结果。Mineralys表示其三期 Launch-HTN 和二期 Advance-HTN 研究在预先规定的主要疗效终点上达到了统计学显著性，并且具有临床意义，同时显示出良好的安全性和耐受性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.